MiMedx Group, Inc. (NASDAQ:MDXG) Insider Kimberly Maersk-Moller Sells 4,106 Shares of Stock

MiMedx Group, Inc. (NASDAQ:MDXG) insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the transaction, the insider now directly owns 310,836 shares in the company, valued at $2,452,496.04. The trade was a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Kimberly Maersk-Moller also recently made the following trade(s):

• On Friday, February 28th, Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock. The stock was sold at an average price of $8.40, for a total transaction of $17,732.40.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG opened at $7.92 on Friday. The firm’s 50-day moving average price is $8.45 and its two-hundred day moving average price is $7.81. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $10.14. The stock has a market capitalization of $1.17 billion, a P/E ratio of 14.40 and a beta of 1.97. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The company had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. As a group, sell-side analysts forecast that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Institutional Investors Weigh In On MiMedx Group

Several large investors have recently made changes to their positions in MDXG. Principal Financial Group Inc. increased its stake in shares of MiMedx Group by 6.3% in the third quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock valued at $328,000 after purchasing an additional 3,292 shares during the period. Entropy Technologies LP acquired a new position in shares of MiMedx Group during the third quarter valued at approximately $64,000. Aigen Investment Management LP acquired a new position in shares of MiMedx Group during the third quarter valued at approximately $83,000. Victory Capital Management Inc. increased its stake in shares of MiMedx Group by 2.8% during the third quarter. Victory Capital Management Inc. now owns 142,350 shares of the company’s stock valued at $841,000 after acquiring an additional 3,901 shares during the period. Finally, Royce & Associates LP increased its stake in shares of MiMedx Group by 5.3% during the third quarter. Royce & Associates LP now owns 972,853 shares of the company’s stock valued at $5,750,000 after acquiring an additional 48,539 shares during the period. Institutional investors and hedge funds own 79.15% of the company’s stock.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a report on Thursday, February 27th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.